The Effects of Chlormadinone Acetate on Lower Urinary Tract Symptoms and Erectile Functions of Patients with Benign Prostatic Hyperplasia: A Prospective Multicenter Clinical Study
Table 1
Baseline characteristics of the patients.
Characteristic
Classification
Number of patients (%)
No
23 (20.2)
Pretreatment drug
Yes
91 (79.8)
1-blocker
91 (79.8)
Anticholinergic agent
9 (7.9)
50 to 65
14 (12.3)
65 to 70
14 (12.3)
70 to 75
39 (34.2)
Age (yrs)
75 to 80
27 (23.7)
≥80
20 (17.5)
Mean ± SD
73.0 ± 6.8
Median
73.0
Range (Min–Max)
57.0–89.0
≤1.0
7 (6.5)
>1.0 and ≤2.0
12 (11.2)
PSA at Week 0† (ng/mL)
>2.0 and ≤4.0
31 (29.0)
>4.0 and ≤6.0
22 (20.6)
>6.0 and ≤10.0
31 (29.0)
>10.0
4 (3.7)
Mean
3.66
20 to 30
22 (20.2)
30 to 40
18 (16.5)
Prostate volume (mL)
40 to 55
31 (28.4)
55 to 80
29 (26.6)
≥80
9 (8.3)
Mean
46.15
PSA: prostate-specific antigen; The day of the first dose.